News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,259 Results
Type
Article (14249)
Company Profile (101)
Press Release (254909)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88670)
Career Advice (470)
Deals (15469)
Drug Delivery (67)
Drug Development (37622)
Employer Resources (50)
FDA (6438)
Job Trends (6349)
News (152068)
Policy (14236)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (456)
Accelerated approval (2)
Adcomms (6)
Allergies (32)
Alliances (23412)
ALS (36)
Alzheimer's disease (404)
Antibody-drug conjugate (ADC) (42)
Approvals (6478)
Artificial intelligence (108)
Autoimmune disease (9)
Automation (3)
Bankruptcy (149)
Best Places to Work (4522)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (20)
Brain cancer (17)
Breast cancer (82)
Cancer (671)
Cardiovascular disease (71)
Career advice (411)
Career pathing (12)
CAR-T (30)
Cell therapy (101)
Cervical cancer (4)
Clinical research (31734)
Collaboration (338)
Compensation (155)
Complete response letters (18)
COVID-19 (771)
CRISPR (20)
C-suite (121)
Cystic fibrosis (37)
Data (659)
Denatured (15)
Depression (9)
Diabetes (79)
Diagnostics (1347)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (61)
Drug pricing (64)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (32460)
Editorial (12)
Employer branding (4)
Employer resources (44)
Events (38186)
Executive appointments (384)
FDA (6870)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (211)
Gene editing (39)
Generative AI (9)
Gene therapy (101)
GLP-1 (354)
Government (1331)
Grass and pollen (2)
Guidances (16)
Healthcare (3656)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (14)
Infectious disease (806)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (49)
Interviews (60)
IPO (5956)
IRA (29)
Job creations (2055)
Job search strategy (377)
Kidney cancer (6)
Labor market (11)
Layoffs (185)
Leadership (3)
Legal (3444)
Liver cancer (19)
Lung cancer (84)
Lymphoma (94)
Machine learning (1)
Management (16)
Manufacturing (152)
MASH (32)
Medical device (1342)
Medtech (1344)
Mergers & acquisitions (9720)
Metabolic disorders (259)
Multiple sclerosis (20)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (6)
Neuroscience (586)
NextGen: Class of 2025 (1602)
Non-profit (610)
Northern California (720)
Now hiring (7)
Obesity (148)
Opinion (121)
Ovarian cancer (22)
Pain (50)
Pancreatic cancer (14)
Parkinson's disease (47)
Partnered (7)
Patents (116)
Patient recruitment (28)
Peanut (10)
People (29008)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8411)
Phase II (13477)
Phase III (11942)
Pipeline (455)
Policy (70)
Postmarket research (1409)
Preclinical (3312)
Press Release (25)
Prostate cancer (47)
Psychedelics (8)
Radiopharmaceuticals (121)
Rare diseases (167)
Real estate (2646)
Recruiting (17)
Regulatory (10287)
Reports (14)
Research institute (586)
Resumes & cover letters (56)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (36)
Series A (36)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Southern California (734)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1637)
State (2)
Stomach cancer (3)
Supply chain (31)
Tariffs (21)
The Weekly (30)
United States (7263)
Vaccines (157)
Venture capitalists (14)
Weight loss (99)
Women's health (8)
Worklife (3)
Date
Today (12)
Last 7 days (177)
Last 30 days (865)
Last 365 days (12095)
2025 (3507)
2024 (12804)
2023 (14596)
2022 (20033)
2021 (20484)
2020 (19364)
2019 (15201)
2018 (11896)
2017 (14117)
2016 (13302)
2015 (15654)
2014 (12555)
2013 (10675)
2012 (11458)
2011 (12028)
2010 (10956)
Location
Africa (314)
Alabama (15)
Alaska (1)
Arizona (55)
Arkansas (3)
Asia (20424)
Australia (2671)
California (1743)
Canada (918)
China (243)
Colorado (69)
Connecticut (71)
Delaware (57)
Europe (40147)
Florida (325)
Georgia (38)
Idaho (9)
Illinois (202)
India (16)
Indiana (133)
Iowa (1)
Japan (92)
Kansas (58)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (261)
Massachusetts (1482)
Michigan (30)
Minnesota (96)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (11)
New Hampshire (6)
New Jersey (765)
New Mexico (7)
New York (509)
North Carolina (395)
North Dakota (2)
Northern California (720)
Ohio (49)
Oklahoma (4)
Oregon (17)
Pennsylvania (442)
Puerto Rico (8)
Rhode Island (9)
South America (505)
South Carolina (2)
Southern California (734)
Tennessee (34)
Texas (229)
Utah (34)
Virginia (72)
Washington D.C. (31)
Washington State (126)
Wisconsin (15)
269,259 Results for "diffusion pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
April 14, 2025
·
10 min read
Press Releases
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
March 3, 2025
·
10 min read
Press Releases
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
March 12, 2025
·
7 min read
Press Releases
World’s First Potential Target Therapy for Diffuse Gastric Cancer Granted Fast Track Designation by the U.S. FDA
February 20, 2025
·
3 min read
Deals
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. (“EIP”), and a reverse stock split of outstanding Diffusion Common Stock (the “Reverse Split”).
August 15, 2023
·
6 min read
Press Releases
Ecotone Releases First Diffusion Transformer AI Model in Vision of Reading the Human Genome as a First Language
Combining Obscure Genetic Mapping Technique with Frontier AI Could Revolutionize Treatment of Rare Genetic Diseases
January 30, 2025
·
1 min read
Pharm Country
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
June 28, 2024
·
10 min read
Press Releases
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma
February 18, 2025
·
3 min read
Press Releases
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
February 13, 2025
·
17 min read
Press Releases
CAR T Cell Therapy Breyanzi® (lisocabtagene maraleucel) Approved for Second-Line Relapsed or Refractory Diffuse Large B-cell Lymphoma
January 14, 2025
·
5 min read
1 of 26,926
Next
